Hyderabad, March 31 -- Granules India Limited on Tuesday said its wholly owned subsidiary, Granules Life Sciences Private Limited (GLS), has received a Voluntary Action Indicated (VAI) classification from the US Food and Drug Administration (US FDA) following an inspection of its manufacturing facility in Shamirpet, on the city outskirts.
The Establishment Inspection Report (EIR) was issued after a current Good Manufacturing Practice (cGMP) and pre-approval inspection (PAI) of the oral solid dosage facility conducted between December 15 and 19, 2025, a release stated.
The inspection has since been closed, with no regulatory action recommended.
Commenting on the development, Krishna Prasad Chigurupati, Chairman and Managing Director, Gran...